ANDS Did they give any more detail on the nature of the "severe immune response " observed ?
No, the CC was very hush hush on those details. That's something they did not want to talk about....
that it might be a strategy to address a patient population that VRTX will not be targeting initially.
I think both will get around to it eventually, once they have more data in hand. Interestingly, PPHM stated on their recent CC they were considering treating coinfected patients with their mab, I don't know if that's a cohort the FDA would allow them to enroll at this early clinical stage or not. They are only treating chronic non-responders at the present time, however, because the mab targets PS, the FDA may allow it as a monotherapy. The same mab yielded some impressive results in a cancer pancreatic model whereas the liver was not compromised, and the mab actually was efficacious on liver metastases. One of the PI's involved with PPHM's HCV studies is pro treating coinfected patients, I think he's quite an advocate for testing new drugs in this patient population. The problem with these patients are their livers are compromised and HCV just further enhances liver decompensation when they have HIV.
katie....
Market Data 
Markets 
AI
